Literature DB >> 27378481

Successful Use of Four Factor-Prothrombin Complex Concentrate for Congenital Factor X Deficiency in the Setting of Neurosurgery.

Alexa J Siddon1, Christopher A Tormey2.   

Abstract

Congenital factor X deficiency is an extremely rare coagulation disorder that can place patients at risk for spontaneous hemorrhage or excessive bleeding in the setting of trauma or invasive procedures. Given the rarity of this disorder, there is little published guidance on how best to prevent or treat bleeding. Herein, we report a case of a 56-year-old white man with congenital factor X deficiency who was scheduled for major neurosurgery and who was treated perioperatively with 4-factor prothrombin complex concentrate (4F-PCC). Doses of 4F-PCC at 15 U per kg, administered immediately preoperatively and once at 24 hours postoperatively, allowed for successful completion of an anterior cervical discectomy and fusion without excessive bleeding. Moreover, no thromboembolic complications were observed. As such, given the wide availability of 4F-PCC, it may be considered as a first-line therapy and an alternative to fresh frozen plasma for factor X deficiencies, particularly in high-risk operative cases. Published by Oxford University Press on behalf of the American Academy of Laboratory Medicine. 2016. This work is written by US Government employees and is in the public domain in the US.

Entities:  

Keywords:  Congenital factor X deficiency; blood banking; coagulation; neurosurgery; prothrombin complex concentrate; transfusion medicine

Mesh:

Substances:

Year:  2016        PMID: 27378481      PMCID: PMC4985779          DOI: 10.1093/labmed/lmw037

Source DB:  PubMed          Journal:  Lab Med        ISSN: 0007-5027


  6 in total

1.  Four-factor prothrombin complex concentrates for warfarin reversal: do real-world outcomes differ from controlled clinical trials?

Authors:  R K Pruthi
Journal:  Transfusion       Date:  2016-04       Impact factor: 3.157

2.  Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists. A meta-analysis.

Authors:  Francesco Dentali; Chiara Marchesi; Matteo Giorgi Pierfranceschi; Mark Crowther; David Garcia; Elaine Hylek; Daniel M Witt; Nathan P Clark; Alessandro Squizzato; Davide Imberti; Walter Ageno
Journal:  Thromb Haemost       Date:  2011-07-28       Impact factor: 5.249

3.  Diagnosis and treatment of inherited factor X deficiency.

Authors:  D L Brown; P A Kouides
Journal:  Haemophilia       Date:  2008-11       Impact factor: 4.287

Review 4.  Clinical Applications of 4-Factor Prothrombin Complex Concentrate: A Practical Pathologist's Perspective.

Authors:  David Unold; Christopher A Tormey
Journal:  Arch Pathol Lab Med       Date:  2015-12       Impact factor: 5.534

5.  Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy.

Authors:  Joost J van Veen; Kingsley K Hampton; Rhona Maclean; Fiona Fairlie; Michael Makris
Journal:  Blood Transfus       Date:  2007-11       Impact factor: 3.443

6.  Surgical treatment for a paraplegic patient induced by congenital factor X deficiency.

Authors:  Weicheng Lin; Jing Zhou; Tianbing Wang; Peixun Zhang
Journal:  Int J Clin Exp Med       Date:  2015-08-15
  6 in total
  1 in total

1.  Inherited Moderate Factor X Deficiency Presenting as Cardiac Tamponade.

Authors:  Tamer Othman; Ayman Abdelkarim; Karen Huynh; An Uche; Jennifer Lee
Journal:  Case Rep Hematol       Date:  2019-09-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.